复方阿齐沙坦酯/氯噻酮药理作用研究进展  

Pharmacological effect of azilsartan medoxomil /chlorthalidone tablet: research advances

作　　者：高越 邱彤 郗砚彬 吴涛 李尧[3] 

机构地区：[1]华润双鹤药业股份有限公司双鹤研究院,北京100102 [2]华润医药集团有限公司创新孵化事业部,北京100020 [3]沈阳药科大学药学院,沈阳110016

出　　处：《国际药学研究杂志》2013年第5期557-559,583,共4页Journal of International Pharmaceutical Research

摘　　要：复方阿齐沙坦酯/氯噻酮(azilsartan medoxomil/chlorthalidone,Edarbyclor)片剂,由一种AT1亚型血管紧张素Ⅱ受体阻滞剂阿齐沙坦酯和噻嗪类利尿剂氯噻酮构成,2011年12月获美国FDA批准用于抗高血压治疗。研究表明,该复方制剂较阿齐沙坦酯或氯噻酮单方具有更显著的降压效果。阿齐沙坦酯/氯噻酮具有独立降压机制,两者合用发挥协同降压的同时合理降低剂量,减少不良反应的发生率。本文综述了复方阿齐沙坦酯/氯噻酮片剂的药物作用机制,药物代谢动力学、安全性及临床研究进展。Azilsartan medoxomil/chlorthalidone （Edarbyclor）tablet is a combined angiotensin receptor blocker and thiazidelike diuretic, and was approved on December 2011 by US FDA for hypertension management. The combination of azilsartan medoxomil and chlorthalidone has efficacy in lowering blood pressure（BP） in hypertensive patients to a greater degree than azilsartan medoxomil or chlorthalidone alone. The two active ingredients of Edarbyclor have two separate mechanisms involved in lowering BP with less dosage and incidence of adverse effect. This article reviews mechanism of action, pharmacokinetics, safety evaluation and advances in clinical research of azilsartan medoxomil/chlorthalidone.

关 键 词：阿齐沙坦酯 氯噻酮 高血压 利尿剂 AT1亚型血管紧张素Ⅱ受体拮抗剂 

分 类 号：R96[医药卫生—药理学]